|
|
Article: NewCo News: Viamet Gets $4 Million Series A For Targeting Metalloenzymes.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Viamet Pharmaceuticals Inc. raised $4 million in a Series A financing to support its preclinical development of small molecules targeting various metalloenzymes involved in infectious disease, inflammation and oncology.
Existing investor Intersouth Partners and new investor Hatteras Venture Partners co-led the round. The money should last "a year or so," according to founding investor and board member Garheng Kong, general partner with Intersouth.
Prior to the current round, Viamet subsisted on about $500,000 in seed funding provided by Intersouth, which incubated the company in its Durham, N.C. facilities. The new money will allow ...